<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Bereavement on Behaviorism and Mental Health</title>
    <link>http://localhost:1313/categories/bereavement/</link>
    <description>Recent content in Bereavement on Behaviorism and Mental Health</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 01 May 2013 10:02:40 +0000</lastBuildDate>
    <atom:link href="http://localhost:1313/categories/bereavement/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Bereavement:  An &#34;Opportunity&#34; for Psychiatry</title>
      <link>http://localhost:1313/posts/bereavement-an-opportunity-for-psychiatry/</link>
      <pubDate>Wed, 01 May 2013 10:02:40 +0000</pubDate>
      <guid>http://localhost:1313/posts/bereavement-an-opportunity-for-psychiatry/</guid>
      <description>&lt;p&gt;There&amp;rsquo;s a new post on Mick Bramham&amp;rsquo;s website called &amp;ldquo;A time to grieve, a time to console, and a time to profit?&amp;rdquo;  You can see it &lt;a href=&#34;http://blog.mythsandrisks.info/2013/04/a-time-to-grieve-time-to-console-and.html&#34;&gt;here&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;You might have thought that, given the adverse publicity that pharma has been receiving in recent years, they would be easing up on their expansionist agenda.&lt;/p&gt;
&lt;p&gt;But you would be wrong.  The &lt;strong&gt;APA has declared open season on bereavement&lt;/strong&gt;, and although DSM-5 won&amp;rsquo;t be released for a few more weeks, &lt;strong&gt;Eli Lilly is already grooming their SNRI Cymbalta as a &amp;ldquo;treatment&amp;rdquo;&lt;/strong&gt; for this pseudo illness.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
